Robert W. Baird Remains a Buy on Inspire Medical Systems (INSP)

Inspire Medical Systems, Inc. (NYSE:INSP) is one of the top oversold NYSE stocks to buy now. Robert W. Baird analyst David Rescott maintained a Buy rating on Inspire Medical Systems, Inc. (NYSE:INSP) on August 5, setting a price target of $150.00.

The rating update came after Inspire Medical Systems, Inc.’s (NYSE:INSP) release of its fiscal Q2 2025 earnings on August 4.

Inspire Medical Systems, Inc. (NYSE:INSP) generated $217.1 million in revenue in fiscal Q2 2025, reflecting an 11% rise over the same quarter last year. Gross margin for the quarter reached 84.0%, while net loss was $3.6 million.

The company reported $13.3 million in adjusted net income, while adjusted diluted earnings per share were $0.45 for fiscal Q2 2025.

Inspire Medical Systems, Inc. (NYSE:INSP) also announced the initiation of the full launch of the Inspire V neurostimulation system in the United States.

Inspire Medical Systems, Inc. (NYSE:INSP) is a medical technology company that develops and commercializes innovative, minimally invasive solutions for obstructive sleep apnea.

The company offers Inspire therapy, which includes implantable components with a pressure-sensing lead, a stimulation lead, and a neurostimulator, operable through a remote control.

While we acknowledge the potential of INSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.